Form 8-K EyePoint, Inc. For: Jul 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
EyePoint Pharmaceuticals settles False Claims Act case for $4.7M
July 17, 2026 4:07 PM EDTEyePoint Pharmaceuticals (NASDAQ: EYPT) has reached a settlement agreement with the U.S. Department of Justice and related federal agencies over alleged civil violations tied to the sales and marketing of its eye care product DEXYCU, which the company commercialized between 2019 and 2023.
According to a press release, the settlement, effective July 17, 2026, resolves potential claims under the False Claims Act, the Civil Monetary Penalties... More
